ORLANDO, Fla., Feb. 23, 2016 /PRNewswire/ --
Who: Moderator Pfenex CEO and Biosimilars Council Chair Dr. Bert Liang
- Panelists
- Ross Day, Director of Pharmacy for Vizient
- Brian Lehman, Manager of Pharmacy Benefits and Policy, Ohio Public Employees Retirement System
- Kevin Nicholson, Vice President of Public Policy and Regulatory Affairs, National Association of Chain Drug Stores
What: Panel Discussion at Generic Pharmaceutical Association (GPhA) Annual Meeting, “Biosimilars Key Issues”
The U.S. Food and Drug Administration (FDA) approval of ZARXIO® in 2015 and its recent backing of Celltrion’s proposed biosimilar to REMICADE® in a recent Arthritis Advisory Committee meeting represented significant steps forward for biosimilars in the U.S. However, they are just thattwo steps. Since the Biologics Price Competition and Innovation Act (BPCIA) was enacted in 2010, only one biosimilar drug has been approved in the U.S. Progress here is dwarfed by that of other regions such as Europe, which already has 20 approvals* and is seeing significantly improved patient access and healthcare savings.
Attend this panel discussion with biosimilar, pharmaceutical, and healthcare industry leaders to explore the numerous key policy issues in play that will directly impact the uptake of biosimilars in the U.S. Learn what needs to be done to educate patients, payers, and providers about biosimilars in order to ensure lower costs, and greater patient access to life-changing treatments.
When: Tuesday, Feb. 23 at 3:45 4:45 p.m. Eastern
Where: JW Marriott Orlando Grande Lakes, 4040 Central Florida Parkway, Orlando, FL 32837
Room: Mediterranean 5 - 8
Why: Learn about the roles that the U.S. FDA, the Centers for Medicare and Medicaid Services (CMS), Congress, payers, prescribers, and the biosimilar industry play with regard to increasing uptake of biosimilars in the U.S.
About Pfenex
Pfenex Inc. (NYSE: PFNX) is a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics and high-value, and difficult-to-manufacture, proteins. The Company’s lead product candidate is PF582, a biosimilar candidate to Lucentis® (ranibizumab), for the potential treatment of patients with retinal diseases. Pfenex has leveraged its Pfenex Expression Technology® platform to build a pipeline of product candidates under development including other biosimilars, as well as vaccines, generics, and next-generation biologics. For additional information, visit Pfenex.com and connect with us on Twitter @Pfenex.
Note: All trademarks mentioned herein are property of their respective owners.
*Source: Generics and Biosimilars Initiative, “Biosimilars approved in Europe,” Feb. 5, 2016.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pfenex-ceo-and-biosimilars-council-chair-dr-bert-liang-to-host-panel-discussion-on-key-biosimilar-issues-at-gpha-annual-meeting-300224646.html
SOURCE Pfenex
